Therapy Areas: Diabetes
Samsung Bioepis launches OPUVIZ across Europe for ophthalmic conditions
29 May 2026 - South Korean biopharmaceutical company Samsung Bioepis Co Ltd announced on Friday the launch of OPUVIZ (aflibercept) 40 mg/mL solution for injection in a vial across Europe.OPUVIZ, an af...
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
21 May 2026 - Health and wellness platform Hims & Hers Health Inc (NYSE:HIMS) announced on Thursday that it has launched access to generic semaglutide through its platform in Canada, marking its f...
Bayer's KERENDIA receives FDA priority review for type 1 diabetes and kidney disease treatment
21 May 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) announced on Thursday that the US Food and Drug Administration (FDA) has accepted and granted Priority Rev...
Dexcom launches Dexcom Flex CGM system for Type 2 diabetes patients in Germany
18 May 2026 - Biosensing technology company DexCom Inc (Nasdaq: DXCM) announced on Monday that it has introduced Dexcom Flex, a new continuous glucose monitoring system designed for adults with Type 2...
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
15 May 2026 - Apotex Inc, a Canada-based global health company, announced on Thursday the commercial launch in Canada of Apo-Semaglutide Injection, a generic equivalent of Ozempic.The product will be ...
Bayer to acquire Perfuse Therapeutics in USD2.45bn deal to expand ophthalmology pipeline
6 May 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) announced on Wednesday that it has agreed to fully acquire Perfuse Therapeutics Inc, strengthening its phar...